INVO Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: INVO) on December 12, 2023. The report addresses a corporate governance action taken by the Board of Directors on the same date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statement data.
Material Changes
The Board of Directors approved an amendment to the Company's Bylaws. Specifically, Article III, Section 8 was amended and restated to lower the quorum requirement for shareholder meetings. The requirement was reduced from a majority of the Company's shares of stock issued and outstanding entitled to vote to one-third of such shares.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, risks, contingencies, or unusual items. The document focuses solely on the procedural change to the Bylaws.
Key Facts for Investor Verification
- The quorum requirement for shareholder meetings has been lowered from a majority to one-third of outstanding voting shares.
- The amendment was approved by the Board of Directors on December 12, 2023.
- The full text of the amendment is attached as Exhibit 3.1 to this filing.
- No financial performance data is included in this specific report.